

## PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/51166>

Please be advised that this information was generated on 2020-12-01 and may be subject to change.

# Very low prevalence of germline *MSH6* mutations in hereditary non-polyposis colorectal cancer suspected patients with colorectal cancer without microsatellite instability

CM Kets<sup>\*,1</sup>, JHJM van Krieken<sup>2</sup>, KM Hebeda<sup>2</sup>, SJ Wezenberg<sup>1</sup>, M Goossens<sup>1,2</sup>, HG Brunner<sup>1</sup>, MJL Ligtenberg<sup>1,2</sup> and N Hoogerbrugge<sup>1</sup>

<sup>1</sup>Department of Human Genetics, Radboud University Nijmegen Medical Centre, 849 Human Genetics, PO Box 9101, 6500 HB Nijmegen, The Netherlands; <sup>2</sup>Department of Pathology, Radboud University Nijmegen Medical Centre, The Netherlands

Hereditary non-polyposis colorectal cancer (HNPCC) is caused by mutations in one of the mismatch repair genes *MLH1*, *MSH2*, *MSH6*, or *PMS2* and results in high-level microsatellite instability (MSI-high) in tumours of HNPCC patients. The MSI test is considered reliable for indicating mutations in *MLH1* and *MSH2*, but is questioned for *MSH6*. Germline mutation analysis was performed in 19 patients with an MSI-high tumour and absence of *MSH2* and/or *MSH6* protein as determined by immunohistochemistry (IHC), without an *MLH1* or *MSH2* mutation, and in 76 out of 295 patients suspected of HNPCC, with a non-MSI-high colorectal cancer (CRC). All 295 non-MSI-high CRCs were analysed for presence of *MSH6* protein by IHC. In 10 patients with an MSI-high tumour without *MSH2* and/or *MSH6* expression, a pathogenic *MSH6* mutation was detected, whereas no pathogenic *MSH6* mutation was detected in 76 patients with a non-MSI-high CRC and normal *MSH6* protein expression. In none of the 295 CRCs loss of *MSH6* protein expression was detected. The prevalence of a germline *MSH6* mutation is very low in HNPCC suspected patients with non-MSI-high CRC. Microsatellite instability analysis in CRCs is highly sensitive to select patients for *MSH6* germline mutation analysis.

British Journal of Cancer (2006) 95, 1678–1682. doi:10.1038/sj.bjc.6603478 www.bjcancer.com

Published online 21 November 2006

© 2006 Cancer Research UK

**Keywords:** MSI; HNPCC; hereditary cancer; *MSH6*

Hereditary non-polyposis colorectal cancer syndrome (HNPCC) is an autosomal-dominant inherited disorder predisposing to colorectal cancer (CRC) and several other cancers at an early age, including endometrial carcinoma. It is clinically suspected by Amsterdam criteria and Bethesda guidelines (Rodriguez-Bigas *et al*, 1997; Umar *et al*, 2004). Hereditary non-polyposis colorectal cancer is caused by mutations in one of the mismatch repair (MMR) genes (*MLH1*, *MSH2*, *MSH6*, and *PMS2*) and is characterised by tumours that show microsatellite instability (MSI). Failure of MMR results in MSI especially in short repetitive sequences. Molecular testing for HNPCC can be performed by testing tumours for MSI and absence of *MLH1*, *PMS2*, *MSH2* and/or *MSH6* as determined by immunohistochemistry (IHC), and germline mutation analysis of MMR genes.

In clinical practice MSI analysis is used as a prescreening tool to select families for further analysis of MMR gene defects. Germline mutations in the *MSH6* MMR gene account for approximately 15–30% of cases of HNPCC (Hampel *et al*, 2005; Barnetson *et al*, 2006; Niessen *et al*, 2006). However *MSH6* mutation carriers were reported to have tumours without an MSI-high pattern (Berends

*et al*, 2002; Hendriks *et al*, 2004; Plaschke *et al*, 2004), whereas in *MLH1* and *MSH2* mutation carriers almost all HNPCC-associated tumours show MSI (Lynch and Lynch, 2005). The reliability of MSI analysis to select patients at risk for *MSH6* mutations is therefore questioned. As germline mutation analysis and IHC of MMR proteins is almost exclusively initiated when MSI analysis shows MSI, we might miss *MSH6* germline mutations.


The aim of this study was to establish the prevalence of *MSH6* mutations in HNPCC suspected patients without MSI in their tumours to investigate the value of MSI analysis to detect *MSH6* mutations.

## MATERIALS AND METHODS

The study is based on 617 tumours of patients or their family members suspected of HNPCC that visited our clinical genetics department in which MSI and subsequent analyses were performed between 1997 until 2006 (Figure 1). In the families analysed in our study MSI analysis is performed in the tumour of the youngest relative available. All findings in this group that were available at 1-1-2006 are included in this study. In 529 tumours of patients a reliable distinction between MSI-high and MSI-stable/low could be made using the standard set of markers (Boland *et al*, 1998). IHC of MMR proteins became available and was applied for from 1999,

\*Correspondence: Dr CM Kets; E-mail: m.kets@antrg.umcn.nl

Received 13 July 2006; revised 10 October 2006; accepted 11 October 2006; published online 21 November 2006



**Figure 1** Flowchart MSI analyses. \*HNPCC spectrum: CRC, endometrial cancer, sebaceous carcinoma, urothelial cell carcinoma, and brain tumour. *MSH6* mut: found pathogenic *MSH6* mutations vs number of patients in which *MSH6* was analysed; *MLH1/MSH2* mut: found pathogenic *MLH1/MSH2* mutations vs number of patients in which *MLH1* and *MSH2* were analysed; not tested: number of patients in which no mutation analyses were performed.

in some cases retrospectively. IHC of the *MSH6* protein was performed in all tumours regardless of MSI results. IHC of all MMR proteins was performed in case of an MSI-high or MSI-low tumour or when other tissue than CRC was tested, such as endometrial cancer, gastric cancer, sebaceous carcinoma, urothelial cell carcinoma, and brain tumours (Rodriguez-Bigas *et al*, 1997). We focused on two separate cohorts of patients; patients with and without MSI in their tumour DNA. The pedigrees made as a part of the genetic counselling procedure were studied for fulfilment of Amsterdam II criteria and Bethesda guidelines (Rodriguez-Bigas *et al*, 1997; Umar *et al*, 2004).

The study was performed according to the rules of the Medical Ethics Committee of the Radboud University Nijmegen Medical Centre.

### Molecular analysis

For MSI analysis normal and tumour tissues were extracted from formalin-fixed and paraffin-embedded tissues. The Bethesda microsatellite panel D2S123, D5S346, D17S250, BAT25, and BAT26 (Boland *et al*, 1998) was used essentially according to methods described previously (Hoogerbrugge *et al*, 2003). A tumour was considered MSI-high when instability was found in  $\geq 2$  out of five markers ( $n = 91$ ) and MSI-stable or low in case of instability in  $\leq 1$  out of five markers ( $n = 438$ ). In 178 samples the mononucleotide marker BAT40 was included in the standard marker set. IHC of the

MMR proteins was performed with the monoclonal antibodies against *MSH6* (Transduction lab code: G70220), *MLH1* (Pharmin-gen code: 51-1327gr), *PMS2* (Pharmin-gen code: 556415), and *MSH2* (Oncogene code: NA26). Germline *MSH6* mutation analysis of the coding regions and splice sites of the *MSH6* gene was performed with a combination of sequence analysis (exon 1, splice acceptor site of exon 10), one-dimensional denaturing gradient gel electrophoresis (exons 2 up to and including 10) essentially as described by Wu *et al* (1999) and multiplex ligation-dependent probe amplification (MRC Holland) for the detection of exon deletions and duplications (exon 1 to 10). Only changes located within 10 nucleotides of the coding region that have not been described as polymorphisms before, are reported.

### Patients with an MSI-high tumour

*MSH6* germline mutation analysis was performed in a group of 19 patients with MSI-high HNPCC-associated tumours and loss of *MSH6* expression in which *MLH1* and *MSH2* mutations were excluded. Nine of these tumours showed loss of *MSH6* expression in the presence of *MSH2* expression and 10 showed loss of both *MSH2* and *MSH6* expression, of which two were difficult to interpret and possibly also showed loss of *PMS2* expression. Microsatellite instability patterns of HNPCC-associated tumours of 12 *MLH1*, 22 *MSH2*, and 10 *MSH6* mutation carriers were studied to compare the instability patterns of tumours of patients with

germline mutations in *MSH6* to those with germline mutations in *MLH1* and *MSH2*.

**Patients with a non-MSI-high tumour**

Three hundred and sixty-three non-MSI-high HNPCC-associated tumours (295 CRC) were analysed out of 335 families. Patients most suspected of HNPCC were selected by fulfilment of at least one of the following criteria; (1) age at diagnosis below 50 years, (2) first degree relative with an HNPCC-related tumour, or (3) second CRC. Of the patients that fulfilled one or more of these criteria a subgroup of 89 patients, 76 of whom had CRC, and one first degree relative, were analysed for *MSH6* germline mutations.

**Statistical analysis**

Categorical variables were compared with the use of the Fisher's exact test using SPSS, version 12.0. A *P*-value of 0.05 is considered as threshold for statistical significance.

**RESULTS**

***MSH6* mutation analysis in patients with an MSI-high tumour**

In a group of 19 patients with both an MSI-high HNPCC-associated tumour and loss of *MSH6* expression, but no detectable defect in *MLH1* or *MSH2*, 10 pathogenic mutations in *MSH6* were

found in nine families (Table 1). Besides the nine different *MSH6* germline mutations found in patients with an MSI-high tumour, two pathogenic mutations in *MSH6* were found in patients in whom MSI analysis could not be performed. The mean age at diagnosis of the 11 index patients from the families with a pathogenic *MSH6* mutation was 44 years (range 36–57). The MSI analyses in nine of these index patients with an *MSH6* mutation was performed on four endometrial, four colorectal, and one urothelial cell cancer. All *MSH6* mutation carriers fulfil one or more Bethesda guidelines and in 64% of the families the Amsterdam II criteria are fulfilled. In the *MSH6* families endometrial cancers occur as frequently as CRCs.

Of the remaining nine tumours with loss of *MSH6* expression, eight tumours also showed loss of *MSH2* expression of which two were difficult to interpret and possibly showed loss of *PMS2* expression as well, suggesting the presence of an as yet undetected *MSH2* (or *PMS2*) germline mutation. One tumour, a CRC developed at age 53, exclusively showed loss of the *MSH6* protein. In this female patient an *MSH6* variant c.2117T>C (p.Phe706Ser) was found of which the pathogenicity is uncertain. She also carries a pathogenic mutation in *BRCA2* (c.3269del (p.Met1080fs)). The patients' mother carries the same *MSH6* variant but not the *BRCA2* mutation. She was diagnosed with endometrial cancer at age 62. Microsatellite instability analysis and IHC on her tumour were inconclusive.

Stability in one or more of the dinucleotide markers occurred significantly more often in colorectal tumours of *MSH6* than of *MLH1* and *MSH2* mutation carriers (Table 2). Stability of

**Table 1** Characteristics of patients with a germline mutation in *MSH6*

Tested cancer and age at diagnosis	Pathogenic mutation <i>MSH6</i>	MSI high									
		Instable mono-nucleotides	Instable di-nucleotides	IHC <i>MSH6</i>	IHC <i>MSH2</i>	Amsterdam criteria II	Bethesda A	Bethesda B	EN in family	CRC in family	
CO 42	c.265-?_457+?dup	2/3	2/3	Neg	Pos	+	–	+	+	+	
EN 57 <sup>a</sup>	c.814G>T (p.Glu272X)	3/3	0/3	Neg	Pos	+	–	+	+	+	
CO 52 <sup>b</sup>	c.651dup (p.Lys218X)	2/2	3/3	Neg	Pos	+	+ EN 37	+	+	+	
CO 58 <sup>b</sup>	c.651dup (p.Lys218X)	3/3	2/3	Neg	Neg	+	+ CO 60	+	+	+	
EN 36	c.3838C>T (p.Gln1280X)	2/2	1/3	Neg	Pos	+	–	+	+	+	
CO 50	c.3273dup (p.Lys1092X))	2/2	2/3	Neg	Pos	+	+CO 46/CO 50	+	+	+	
EN 43	c.3261dup (p.Phe1088fs)	2/2	3/3	Neg	Neg	+	–	+	+	–	
CO 39	c.3261del (p.Phe1088fs)	2/2	2/3	Neg	Pos	+	–	+	–	+	
EN 38	c.1135_1139del (p.Arg379X)	2/2	1/3	Neg	Pos	–	+O 38	–	+	–	
UR 56	c.1-?_475+? del	3/3	0/3	Neg	Pos	–	+UR 57SEB 59	+	–	+	
EN 38	c.3678_3706dup (p.Ala1236fs)	nt		nt	nt	–	–	+	+	–	
CO 47	c.2815C>T (p.Gln939X)	nt <sup>c</sup>		nt	nt	–	–	+	–	+	
Total						7/11 (64%)	4/11 (36%)	10/11 (91%)	8/11 (73%)	8/11 (73%)	

Bethesda A: Proband with two HNPCC-related cancers, Bethesda B: Proband and first degree relative with HNPCC-related cancer, one diagnosed <50 y. EN = endometrial cancer, CO = colorectal cancer, UR = urothelial cell carcinoma, SEB = sebaceous adenoma, O = ovarian cancer, Neg = negative, Pos = positive, nt = not tested; IHC = immunohistochemistry; MSI = microsatellite instability. <sup>a</sup>This patient also has an UV c.65G>C (p.Gly22Ala) in *MLH1* <sup>b</sup>Patients from same family. <sup>c</sup>Tumour of patients father showed MSI and no *MSH6* expression.

**Table 2** Results of the MSI analysis in *MSH6*, *MLH1* and *MSH2* mutation carriers

MSI pattern	<i>MSH6</i> mutation carriers	<i>MLH1</i> and <i>MSH2</i> mutation carriers	<i>P</i> -value Fisher exact
One or more of three dinucleotides <sup>a</sup> stable			
CRC	4/5 (80%)	4/22 (18%)	<b>0.017</b>
Non CRC	4/5 (80%)	1/6 (17%)	NS
One or more mononucleotides <sup>b</sup> stable			
CRC only	1/5 (20%)	2/26 (8%)	NS
Non CRC	0/5 (0%)	0/6 (0%)	NS

NS = not significant; CRC = colorectal cancer; MSI = microsatellite instability. <sup>a</sup>D2S123, D5S346, and D17S250. <sup>b</sup>BAT25 and BAT26.

mononucleotide markers is uncommon in tumours of *MSH6* as well as *MLH1* and *MSH2* mutation carriers.

### MSH6 mutation analysis in patients with a non-MSI-high tumour

Immunohistochemical staining showed *MSH6* expression in all 295 non-MSI-high CRCs and in 67 out of 68 other non-MSI-high HNPCC-related tumours (Table 3).

A subgroup of patients with the highest suspicion of HNPCC, was tested for the presence of *MSH6* germline mutations. In none of the 76 patients with CRC, or in the 13 patients with other HNPCC-related tumours a pathogenic germline mutation in *MSH6* was detected. One non-MSI-high tumour of metastatic tumour tissue (most probably derived from a CRC) of a deceased patient showed loss of *MSH6* expression, in presence of *MLH1* and *MSH2* expression. Because mutation analysis could not be performed in the deceased patient, mutation analysis in her brother was performed. No mutation in *MSH6* was detected (Table 4).

Silent variants c.3852G>A, c.2154C>T, c.1068T>C, and c.3246G>T were found. None of these are predicted to affect splicing and thus do not seem to have functional consequences. The missense variant c.3101G>C (p.Arg1034Pro) that was found

in a female patient with CRC at age 43 might be pathogenic. As the carcinoma was not available the MSI and IHC analyses were performed in an adenoma, which might have decreased the sensitivity of the analyses. Segregation analysis in the family showed that her brother who had a glioma, and the mother who had two sisters with anamnestic endometrial cancer did not carry the *MSH6* variant, making the pathogenicity of this variant less likely.

### DISCUSSION

In this study, not one pathogenic germline *MSH6* mutation was detected in HNPCC suspected patients with a non-MSI-high CRC or HNPCC-related tumour.

Previous studies suggested that the sensitivity of MSI analysis to predict an *MSH6* mutation is low and that MSI should not be used as a selection criterion for *MSH6* mutation analysis (Wu *et al*, 1999), finding microsatellite stable or low patterns in 17% up to 50% (Berends *et al*, 2002; Hendriks *et al*, 2004; Plaschke *et al*, 2004; Niessen *et al*, 2006; Pinto *et al*, 2006) of HNPCC-associated tumours of *MSH6* mutation carriers. However careful consideration of previous studies is required as part of the conclusions are based on *MSH6* missense mutations of unknown pathogenicity or testing a sporadic tumour within an HNPCC family (a phenocopy) as suggested by positive immunostaining of *MSH6* in the tumour. These have an unfavourable effect on the sensitivity of MSI analysis. In addition MSI analysis on endometrial cancer, the most frequent tumour in female *MSH6* mutation carriers might decrease its sensitivity, as it is known that the instability in these tumours is generally less pronounced (Wijnen *et al*, 1999; Hendriks *et al*, 2004).

*MSH6* mutations result in a weaker mutator phenotype (Kolodner *et al*, 1999), which may be explained by the major function of *MSH6* to correct base-base mismatches and single nucleotide deletion loops but not larger deletion loops (Parc *et al*, 2000). Like in previous studies (Kolodner *et al*, 1999; Verma *et al*, 1999; Parc *et al*, 2000) our study shows that mononucleotide markers but not dinucleotide markers are sensitive to show instability in tumours of *MSH6* mutation carriers. The sensitivity of MSI analysis therefore depends on the microsatellite markers used. Enlarging the standard (Bethesda) marker set (Boland *et al*, 1998) with a mononucleotide marker (like BAT40) will increase the sensitivity of MSI analysis by minimising the chance of missing tumours with *MSH6* inactivation. As data on MSI analysis of other non-colorectal HNPCC-related tumours with defective MMR are insufficient, we recommend additional IHC of *MLH1*, *PMS2*, *MSH2*, and *MSH6* proteins when MSI analysis is performed on non-colorectal HNPCC-related cancers. Immunohistochemical staining of MMR proteins will also improve the interpretation of MSI patterns when a low percentage of tumour cells or an adenoma is tested or when only one mononucleotide marker shows instability (MSI low). When a patient is excluded from further HNPCC analysis based on a non-MSI-high pattern in

**Table 3** Overview of microsatellite stable/low tumours

	Patient with non-MSI-high tumour and loss of <i>MSH6</i> expression	Patients with non-MSI-high tumours and positive <i>MSH6</i> expression	Selected group of patients with non-MSI-high tumours and positive <i>MSH6</i> expression without a pathogenic mutation in <i>MSH6</i>
<b>Colorectal ca</b>		295	76
Age <50 yr		171 (58%)	62 (82%)
<b>Other HNPCC-related neoplasia</b>	1	67	13
Endometrial ca		15	3
Gastric ca		3	
Sebaceous ca		4	
Urothelial cell ca		1	
Brain tumour		1	
Metastatic tissue	1 <sup>a</sup>	7	
Small bowel		1	
Adenoma			
Colon		34	10
Duodenum		1	
Age <50 yr	0	34 (51%)	9 (69%)

MSI = microsatellite instability; HNPCC = hereditary non-polyposis colorectal cancer; ca = cancer. <sup>a</sup>Mutation analysis in the patients' brother showed no *MSH6* mutation.

**Table 4** MSI-test result and IHC protein expression pattern of tumours from patients tested for the presence of a *MSH6* germline mutation

MSI	MSI high			MSI stable/low	
	MSH6- MSH2+ MLH1+ PMS2+	MSH6- MSH2- MLH1+ PMS2+	MSH6- <sup>a</sup> MSH2- <sup>a</sup> MLH1+ <sup>a</sup> PMS2- <sup>a</sup>	MSH6-	MSH6+
No pathogenic mutation in <i>MSH6</i>	1 <sup>b</sup>	6	2	1 <sup>c</sup>	89
Pathogenic mutation in <i>MSH6</i>	8	2			

IHC = immunohistochemistry; MSI = microsatellite instability. <sup>a</sup>IHC difficult to interpret. <sup>b</sup>With *MSH6* variant c.2117T>C (p.Phe706Ser). <sup>c</sup>Mutation analysis was performed in the patients' brother.

tumour DNA, a second MSI analysis in the family should always be considered to avoid missing a germline mutation because of an initial test in a phenocopy.

From previous studies we know, that in *MSH6* mutation carriers CRC occurs at older age than in *MLH1* and *MSH2* mutation carriers (Hendriks et al, 2004). In our study, the patients with MSI-stable/low tumours that were analysed for *MSH6* mutations were mainly diagnosed before the age of 50. This selection is not expected to have a large influence, because MSI analysis in the families in our study is performed in the tumour of the youngest relative available. The mean age of diagnosis in *MSH6* mutation carriers is above 50, but the occurrence of one relative below 50 is expected to be present in most of the *MSH6* families. The pedigrees of the diagnosed *MSH6* families in our study all contained an affected relative diagnosed below 50 years of age.

The prevalence of *MSH6* mutation carriers in HNPCC suspected CRC patients is low, as is demonstrated by the fact that we detected an *MSH6* mutation in only about 1% of these patients. All these mutations were found in patients with an MSI-high tumour. Data

from previous studies (Berends et al, 2002; Hendriks et al, 2004; Plaschke et al, 2004; Barnetson et al, 2006; Niessen et al, 2006) show that approximately 15% of colorectal tumours of *MSH6* mutation carriers do not have an MSI-high pattern, whereas they do show loss of *MSH6* expression and thus might be the result of the *MSH6* germline mutation. On the other hand, approximately 5% of colorectal tumours of *MSH6* mutation carriers do show neither an MSI-high pattern nor loss of *MSH6* expression and thus might have arisen independent from the genetic background of the carrier. Based on our finding of the low incidence of *MSH6* mutations in HNPCC-suspected CRC patients and the percentage of non-MSI-high tumours in *MSH6* mutation carriers from the literature, the probability of missing a mutation by not performing mutation analyses in patients with non-MSI-high CRCs is expected to be extremely low. This is confirmed by the fact that we did not find any non-MSI-high CRC with loss of *MSH6* expression, nor a germline *MSH6* mutation in any of the patients with a non-MSI-high tumour. Our findings show that MSI analysis is highly suited to trace CRC of carriers of *MSH6* germline mutations.

## REFERENCES

- Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R, Porteous ME, Campbell H, Dunlop MG (2006) Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. *N Engl J Med* 354: 2751–2763
- Berends MJ, Wu Y, Sijmons RH, Mensink RG, van der ST, Hordijk-Hos JM, de Vries EG, Hollema H, Karrenbeld A, Buys CH, van der Zee AG, Hofstra RM, Kleibeuker JH (2002) Molecular and clinical characteristics of *MSH6* variants: an analysis of 25 index carriers of a germline variant. *Am J Hum Genet* 70: 26–37
- Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 58: 5248–5257
- Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la CA (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N Engl J Med* 352: 1851–1860
- Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, Sandkuijl L, Moller P, Genuardi M, Van HH, Tops C, van PM, Verkuijlen P, Kenter G, Van MA, Meijers-Heijboer H, Tan GB, Breuning MH, Fodde R, Wijnen JT, Brocker-Vriends AH, Vasen H (2004) Cancer risk in hereditary nonpolyposis colorectal cancer due to *MSH6* mutations: impact on counseling and surveillance. *Gastroenterology* 127: 17–25
- Hoogerbrugge N, Willems R, Van Krieken HJ, Kiemeneij LA, Weijmans M, Nagengast FM, Arts N, Brunner HG, Ligtenberg MJ (2003) Very low incidence of microsatellite instability in rectal cancers from families at risk for HNPCC. *Clin Genet* 63: 64–70
- Kolodner RD, Tytell JD, Schmeits JL, Kane MF, Gupta RD, Weger J, Wahlberg S, Fox EA, Peel D, Ziogas A, Garber JE, Syngal S, nton-Culver H, Li FP (1999) Germ-line *msh6* mutations in colorectal cancer families. *Cancer Res* 59: 5068–5074
- Lynch HT, Lynch PM (2005) Molecular screening for the Lynch syndrome—better than family history? *N Engl J Med* 352: 1920–1922
- Niessen RC, Berends MJ, Wu Y, Sijmons RH, Hollema H, Ligtenberg MJ, de Walle HE, de Vries EG, Karrenbeld A, Buys CH, van der Zee AG, Hofstra RM, Kleibeuker JH (2006) Identification of mismatch repair gene mutations in young colorectal cancer patients and patients with multiple HNPCC-associated tumours. *Gut* Published on line first 24 april 2006. doi:10.1136/gut.2005.090159
- Parc YR, Halling KC, Wang L, Christensen ER, Cunningham JM, French AJ, Burgart LJ, Price-Troska TL, Roche PC, Thibodeau SN (2000) *MSH6* alterations in patients with microsatellite instability-low colorectal cancer. *Cancer Res* 60: 2225–2231
- Pinto C, Veiga I, Pinheiro M, Mesquita B, Jeronimo C, Sousa O, Fragoso M, Santos L, Moreira-Dias L, Baptista M, Lopes C, Castedo S, Teixeira MR (2006) *MSH6* germline mutations in early-onset colorectal cancer patients without family history of the disease. *Br J Cancer* 95: 752–756
- Plaschke J, Engel C, Kruger S, Holinski-Feder E, Pagenstecher C, Mangold E, Moeslein G, Schulmann K, Gebert J, von Knebel DM, Ruschoff J, Loeffler M, Schackert HK (2004) Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic *MSH6* germline mutations compared with families with *MLH1* or *MSH2* mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. *J Clin Oncol* 22: 4486–4494
- Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perucho M, Smyrk T, Sobin L, Srivastava S (1997) A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. *J Natl Cancer Inst* 89: 1758–1762
- Umar A, Boland CR, Terdiman JP, Syngal S, de la CA, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 96: 261–268
- Verma L, Kane MF, Brassett C, Schmeits J, Evans DG, Kolodner RD, Maher ER (1999) Mononucleotide microsatellite instability and germline *MSH6* mutation analysis in early onset colorectal cancer. *J Med Genet* 36: 678–682
- Wijnen J, De LW, Vasen H, van der KH, Moller P, Stormorken A, Meijers-Heijboer H, Lindhout D, Menko F, Vossen S, Moeslein G, Tops C, Brocker-Vriends A, Wu Y, Hofstra R, Sijmons R, Cornelisse C, Morreau H, Fodde R (1999) Familial endometrial cancer in female carriers of *MSH6* germline mutations. *Nat Genet* 23: 142–144
- Wu Y, Berends MJ, Mensink RG, Kempinga C, Sijmons RH, van der Zee AG, Hollema H, Kleibeuker JH, Buys CH, Hofstra RM (1999) Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with *MSH6* germline mutations. *Am J Hum Genet* 65: 1291–1298